fig2

Figure 2. Hypothetical ctDNA biomarker levels during tumor development and therapy. After tumor removal, the biomarker level drops significantly and will remain low in the case the patient is cured. Early detection of minimal residual disease (MRD) by ctDNA allows additional treatment (e.g., chemo-, radio-, or hormone therapy) with the intent of cure, much earlier than with clinical imaging methods.